Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.480
-0.130-2.32%
Volume:79.10M
Turnover:436.47M
Market Cap:102.38B
PE:36.10
High:5.640
Open:5.520
Low:5.475
Close:5.610
52wk High:8.901
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.81
T/O Rate:0.42%
Dividend:0.12
Dividend Rate:2.19%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.69
PE(LYR):36.10
PS:2.60

Loading ...

Sino Biopharmaceutical Stock Slides 2.3% in Hong Kong

Dow Jones
·
31 mins ago

Sino Biopharmaceutical Stock Slides 4.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Yesterday

UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick

Stock News
·
Yesterday

Movement Alert|SBP GROUP Declines 3.08% in Regular Trading, Trading at 5.67 HKD

Market Focus
·
Yesterday

SBP Group Unveils Preclinical Findings for Oral STAT6 Degrader TQH5528 at ERS 2026

Stock News
·
Sep 08

Sino Biopharm Presents ERS 2026 Preclinical Data for Oral STAT6 Degrader Tqh5528

Reuters
·
Sep 08

Sino Biopharm CEO Tse Says AI, Internationalization Anchor Counter-Cyclical Growth Strategy

Reuters
·
Sep 08

Movement Alert|SBP GROUP Rises 3.02% in Regular Trading, TQC3721 Inhaler Phase I Clinical Data Presented at European Respiratory Society Annual Meeting

Market Focus
·
Sep 08

Hong Kong Stock Market Update | SBP GROUP (01177) Climbs Nearly 3% After TQC3721 Inhalation Powder Data Presented at ERS 2026

Stock News
·
Sep 08

SBP Group Unveils Positive Phase I Data for TQC3721 Dry-Powder Inhaler at ERS 2026

Bulletin Express
·
Sep 07

Sino Biopharma Reports Phase I Data Showing Tqc3721 Dry Powder Inhaler Boosts COPD Lung Function in Dose-Ranging Trial

Reuters
·
Sep 07

Sino Biopharmaceutical Stock Slides 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 07

Wuhan Dazhong Dental Proposes Wang Hong as Executive Director to Replace Guo Jiaping

Reuters
·
Sep 04

Sino Biopharma Gets US FDA Investigational New Drug Approval for Tumor Drug

MT Newswires Live
·
Sep 04

Sino Biopharm Says FDA Clears IND for Tqb6426 GPC3 ADC Trial in Advanced Tumors

Reuters
·
Sep 03

Sino Biopharmaceutical - Application for Clinical Trial on Tqb6426 "Gpc3 ADC" Approved by FDA

THOMSON REUTERS
·
Sep 03

Sino Biopharmaceutical Stock Rises 6.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 03

SBP Group Surges Over 4% in Morning Trade on FDA Clearance for TQB6426

Deep News
·
Sep 03

Movement Alert|SBP GROUP Rises 3.33% in Regular Trading, Core ADC Drug TQB2102 Phase III Trial Hits Primary Endpoint

Market Focus
·
Sep 03

Sino Biopharm Files HKEX Next-Day Return Disclosing Share Buyback for Cancellation

Reuters
·
Sep 01